Simvastatin Attenuates Plaque Inflammation

Tahara, Nobuhiro; Kai, Hisashi; Ishibashi, Masatoshi; Nakaura, Hiroyuki; Kaida, Hayato; Baba, Kenkichi; Hayabuchi, Naofumi; Imaizumi, Tsutomu

doi:10.1016/j.jacc.2006.03.069

Cited by 605 publications

(167 citation statements)

References 20 publications

Supporting

Mentioning

155

Contrasting

Unclassified

Order By: Relevance

“…4). 18 F-FDG PET is increasingly used for monitoring response to therapy in a variety of malignancies (30), and a similar role for 18 F-FDG PET in inflammatory conditions is beginning to be explored (31)(32)(33). If 18 F-FDG uptake proves capable of accurate, early assessment of response to therapy in patients with Crohn disease, this information may enable modification or discontinuation of ineffective drug therapies that carry significant toxicities or expense.…”

Section: Discussionmentioning

confidence: 99%

Low-Dose ¹⁸F-FDG PET/CT Enterography: Improving on CT Enterography Assessment of Patients with Crohn Disease

Shyn¹,

Mortelé²,

Britz-Cunningham³

et al. 2010

J Nucl Med

View full text Add to dashboard Cite

The purpose of this study was to evaluate the diagnostic efficacy of low-dose, combined 18 F-FDG PET/CT enterography (PET/CTE), compared with CT enterography (CTE) alone, in the assessment of patients with Crohn disease. Methods: Thirteen patients with Crohn disease were prospectively enrolled in this pilot study and underwent abdominal-pelvic 18 F-FDG PET/CTE using neutral oral and intravenous contrast medium. The effective dose from PET/CTE was 17.7 mSv for the first 4 patients and 8.31 mSv for the last 9 patients. Six patients underwent surgical resection of the bowel, and 7 patients underwent colonoscopy with biopsies within 27 d (mean, 12 d) of PET/CTE. PET/CTE and CTE images were each visually assessed for Crohn disease involvement in 54 bowel segments with pathology correlation. Extraintestinal findings were recorded. A CTE severity score, maximum standardized uptake value (SUVmax), SUVmax ratio, simplified endoscopic score, and clinical parameters were correlated with pathology inflammation grade, on a per-patient basis and on a per-bowel-segment basis, using Spearman correlation. Results: In 3 (23.1%) of 13 patients, 18 F-FDG uptake using PET/CTE revealed active inflammation in a bowel segment not evident using CTE (n 5 2) or revealed an enterocolic fistula missed with CTE (n 5 1). Visual interpretation of both PET/CTE and CTE images detected the presence of disease in all bowel segments with more than mild inflammation (sensitivity, 100%; specificity, 89.7%; positive predictive value, 78.9%; and negative predictive value, 100%). Correlation to inflammation grade per patient was the strongest for the SUVmax ratio (0.735, P 5 0.004) and SUVmax (0.67, P 5 0.013), as compared with the CTE score (0.62, P 5 0.024). Correlation with inflammation per bowel segment was higher for the CTE score (0.79, P , 0.0001) than the SUVmax ratio (0.62, P , 0.0001) or SUVmax (0.48, P , 0.0001). SUVmax correlated strongly with serum C-reactive protein (0.82, P 5 0.023), but CTE score did not. Conclusion: Low-dose 18 F-FDG PET/CTE, compared with CTE, may improve the detection and grading of active inflammation in patients with Crohn disease. PET/CTE also may reveal clinically significant findings, such as enterocolic fistula, not evident on PET or CTE alone.

show abstract

Section: Discussionmentioning

confidence: 99%

Low-Dose ¹⁸F-FDG PET/CT Enterography: Improving on CT Enterography Assessment of Patients with Crohn Disease

Shyn¹,

Mortelé²,

Britz-Cunningham³

et al. 2010

J Nucl Med

View full text Add to dashboard Cite

show abstract

“…[144][145][146][147] La señal vascular cuantitativa de PET FDG ha sido ampliamente utilizada como un objetivo subrogado para probar los efectos de drogas antiinflamatorias en los estudios clínicos. [148][149][150][151][152][153][154][155] La PET con FDG se está usando activamente como un objetivo subrogado en muchos estudios en curso de ateroesclerosis. Más recientemente, otros agentes de imágenes novedosos dirigidos se han utilizado con PET para caracterizar la inflamación 134,156-160 y otros aspectos de la biología de la placa que incluyen la neoangiogénesis 161 y microcalcificación, 162 y también en complicaciones de la ateroesclerosis 163 en animales experimentales y seres humanos.…”

Section: Imágenes De Infarto De Miocardiounclassified

The Future of Cardiovascular Imaging

2016

View full text Add to dashboard Cite

O ver the past 2 decades, we have witnessed an explosive expansion in the armamentarium of noninvasive and invasive imaging technologies capable of providing detailed information about the structure and function of the heart and vasculature. Many of these technologies are integrative (eg, positron emission tomography and computed tomography, positron emission tomography and MRI), thereby compounding the unique strengths of the component technologies to achieve unprecedented improvements to our ability to diagnose disease, improve patient care, and advance biomedical research. In addition, the miniaturization of imaging devices with dramatic increases in sensitivity and spatial resolution, coupled with the development of quantitative molecular imaging approaches for evaluating physiology and pathobiology at the cellular and molecular levels, provides a unique platform for a new era in diagnostic imaging. The crucial role of imaging in early phenotyping of disease, risk assessment, and management guidance is expanding rapidly in ways previously thought unrealistic.Along with clinical, molecular, and genomewide association studies, structural and functional quantitative imaging already plays a critical role in phenotyping cardiovascular disease. Unique strengths of imaging phenotyping include its ability to provide precise, organ-specific anatomic localization and quantification of disease traits, to demonstrate and quantify involvement of other organs in cardiac disease, to provide an opportunity to investigate the time course of disease-specific molecular events in vivo, and to track their response to therapy. In so doing, quantitative structural and functional imaging can provide a nuanced description of disease burden (eg, atherosclerosis, myocarditis), disease subtypes (eg, amyloidosis), and, importantly, the relationship between the specific phenotype and outcomes, thereby informing treatment strategies and allowing more personalized approaches to patient management.Our objectives for this article are to (1) provide a viewpoint regarding the evolving role of cardiovascular imaging in biomedical research and clinical practice, (2) discuss the challenges associated with clinical translation of imaging innovations and the opportunities for multimodality imaging in the changing paradigm of value-based medicine, and (3) briefly outline future challenges and opportunities including the requirements for training future generations of imaging scientists and clinical specialists. Unlike traditional reviews that provide a detailed discussion of the role of 1 or more imaging modalities in cardiovascular (CV) disease, our discussion will focus on the potential role of imaging in what we believe are key areas of the translational highway with specific examples on how structural and functional imaging may contribute to scientific discovery, diagnosis, risk stratification, and patient management in each of those areas. Redefining the Role of Imaging Across the Continuum of Biomedical Research and Clinical Practice Translati...

show abstract

“…Statins, for example, have been demonstrated to reduce both carotid atherosclerotic plaque burden 4,5 and plaque composition 6 on magnetic resonance (MR), as well as reducing vascular 18F-FDG uptake on PET. 7 Other medications, such as cholesterol ester transfer protein inhibitors, have by comparison failed to reduce 18F-FDG activity mirroring the similarly disappointing effects of these drugs on clinical outcomes. 8,9 The recent emergence of hybrid PET/MR systems offers major potential in this field, allowing combined, detailed assessment of large vessel plaque burden (MR), composition (MR), and activity (PET) at radiation doses considerably lower than possible…”

Section: See Article By Figueroa Et Almentioning

confidence: 99%

Can Imaging Improve Our Understanding of Cardiovascular Pathophysiology?

Dweck

Hyafil

2016

Circ: Cardiovascular Imaging

View full text Add to dashboard Cite

Simvastatin Attenuates Plaque Inflammation

Cited by 605 publications

References 20 publications

Low-Dose ¹⁸F-FDG PET/CT Enterography: Improving on CT Enterography Assessment of Patients with Crohn Disease

Low-Dose ¹⁸F-FDG PET/CT Enterography: Improving on CT Enterography Assessment of Patients with Crohn Disease

The Future of Cardiovascular Imaging

Can Imaging Improve Our Understanding of Cardiovascular Pathophysiology?

Contact Info

Product

Resources

About

Simvastatin Attenuates Plaque Inflammation

Cited by 605 publications

References 20 publications

Low-Dose 18F-FDG PET/CT Enterography: Improving on CT Enterography Assessment of Patients with Crohn Disease

Low-Dose 18F-FDG PET/CT Enterography: Improving on CT Enterography Assessment of Patients with Crohn Disease

The Future of Cardiovascular Imaging

Can Imaging Improve Our Understanding of Cardiovascular Pathophysiology?

Contact Info

Product

Resources

About

Low-Dose ¹⁸F-FDG PET/CT Enterography: Improving on CT Enterography Assessment of Patients with Crohn Disease

Low-Dose ¹⁸F-FDG PET/CT Enterography: Improving on CT Enterography Assessment of Patients with Crohn Disease